Free shipping on all orders over $ 500

Rezivertinib

Cat. No. M45386

All AbMole products are for research use only, cannot be used for human consumption.

Rezivertinib Structure
Synonym:

BPI-7711

Price and Availability

For this product's availability, delivery time and price, please email [email protected] directly or click the "Inquiry Now" button below.

Quality Control & Documentation
Biological Activity

Rezivertinib is an orally effective, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with high potency against common activating EGFR and resistant T790M mutations.Rezivertinib exhibits excellent CNS penetration and antitumor activity.

Chemical Information
Molecular Weight 486.57
Formula C27H30N6O3
CAS Number 1835667-12-3
Form Solid
Solubility (25°C) DMSO >100 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Sheng Yang, et al. Lung Cancer. Central nervous system efficacy of rezivertinib (BPI-7711) in advanced NSCLC patients with EGFR T790M mutation: A pooled analysis of two clinical studies

[2] Sally C M Lau, et al. J Thorac Oncol. And Still They Come Over Troubled Waters: Can Asia's Third-Generation EGFR Tyrosine Kinase Inhibitors (Furmonertinib, Aumolertinib, Rezivertinib, Limertinib, Befotertinib, SH-1028, and Lazertinib) Affect Global Treatment of EGFR+ NSCLC

[3] Yuankai Shi, et al. J Thorac Oncol. Efficacy and Safety of Rezivertinib (BPI-7711) in Patients With Locally Advanced or Metastatic/Recurrent EGFR T790M-Mutated NSCLC: A Phase 2b Study

[4] Yuankai Shi, et al. J Thorac Oncol. Safety, Efficacy, and Pharmacokinetics of Rezivertinib (BPI-7711) in Patients With Advanced NSCLC With EGFR T790M Mutation: A Phase 1 Dose-Escalation and Dose-Expansion Study

[5] Misako Nagasaka, et al. J Thorac Oncol. Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC

Related EGFR/HER2 Products
Sevabertinib

Sevabertinib is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor with antitumor activity.
BPIQ-I

BPIQ-I (PD 159121) is a potent and ATP-competitive EGFR tyrosine kinase inhibitor..
HKI-357 

HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 with IC50s of 34 nM and 33 nM, respectively.
SJF-1528 

SJF-1528 is a potent EGFR PROTAC degrader with DC50 values of 39.2 nM and 736.2 nM for wild-type EGFR in OVCAR8 cells and Exon 20 Ins mutated EGFR in HeLa cells.
CH7233163 

CH7233163 is a noncovalent ATP-competitive inhibitor for EGFR-Del19/T790M/C797S.
  Catalog
Abmole Inhibitor Catalog




Keywords: Rezivertinib, BPI-7711 supplier, EGFR/HER2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.


 
Get to Know Us
Customer Support
Resources
Contact Us

Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.